Applied Molecular Transport Completes Enrollment of Phase 2 LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the company has completed enrollment of the Phase 2 LOMBARD trial for AMT-101 in 105 patients with moderate-to-severe ulcerative colitis (UC). AMT-101 is an investigational, once-daily, GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier molecule.
“Completing enrollment in our LOMBARD trial marks an important milestone in the ongoing development of oral AMT-101 as a potential treatment for ulcerative colitis,” said Bittoo Kanwar, M.D., chief medical officer of AMT. “We look forward to reporting top-line data, including clinical remission, from the Phase 2 LOMBARD trial. We would like to thank our patients and clinical sites around the globe for participating in this trial.”
About Ulcerative Colitis
About Applied Moecular Transport Inc.
AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.
Investor Relations Contact: